A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease

NCT02760602 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
26
Enrollment
INDUSTRY
Sponsor class

Stopped Insufficient scientific evidence that solanezumab would likely demonstrate a meaningful benefit to participants with prodromal AD as defined by study protocol.

Conditions

Interventions

Sponsor

Eli Lilly and Company